- All Courts
- Federal Courts
- Bankruptcies
- PTAB
- ITC
Filters
Like full text docket searches?
Get docket alerts, perform legal research, get updates of major decisions and orders, use our advanced analytics, and more. Request a Demo or create your account.
Date Filed
Dollars
Find cases based on dollar amount with searches like:
$100k-$10M.
Read the details here.
Displaying 189-203 of
250 results
2010 Exhibit: Complaint filed 9122018
Document
IPR2020-01053, No. 2010-58 Exhibit - Complaint filed 9122018 (P.T.A.B. Sep. 18, 2020)
|
|
Cite Document
2034 Exhibit: Seroquel XR
Document
IPR2020-01053, No. 2034-83 Exhibit - Seroquel XR (P.T.A.B. Sep. 18, 2020)
|
|
Cite Document
3002 Exhibit: E Mail Requesting POP Review
Document
IPR2020-01053, No. 3002 Exhibit - E Mail Requesting POP Review (P.T.A.B. Jan. 7, 2022)
|
|
Cite Document
2143 Exhibit: Patent Owners Demonstratives
Document
IPR2020-01053, No. 2143 Exhibit - Patent Owners Demonstratives (P.T.A.B. Aug. 9, 2021)
|
|
Cite Document
1055 Exhibit: Public Version Reisetter Deposition Transcript
Document
IPR2020-01053, No. 1055 Exhibit - Public Version Reisetter Deposition Transcript (P.T.A.B. Jun. 24, 2021)
|
|
Cite Document
1054 Exhibit: Public Version Stahl Deposition Transcript
Document
IPR2020-01053, No. 1054 Exhibit - Public Version Stahl Deposition Transcript (P.T.A.B. Jun. 24, 2021)
|
|
Cite Document
3001 Exhibit: Exhibit 3001
Document
IPR2020-01053, No. 3001 Exhibit - Exhibit 3001 (P.T.A.B. Dec. 7, 2021)
|
|
Cite Document
2002 Exhibit: ZYPREXA olanzapine Label 2000
Document
IPR2020-01053, No. 2002 Exhibit - ZYPREXA olanzapine Label 2000 (P.T.A.B. Sep. 18, 2020)
|
|
Cite Document
1002 Exhibit: EX 1002, Declaration of Dr Thomas Kosten, MD
Document
IPR2020-01053, No. 1002 Exhibit - EX 1002, Declaration of Dr Thomas Kosten, MD (P.T.A.B. Jun. 5, 2020)
|
|
Cite Document
2053 Exhibit: Lombardo et al, Two 6 Week, randomized, Double Blind, Placebo Con...
Document
IPR2020-01053, No. 2053 Exhibit - Lombardo et al, Two 6 Week, randomized, Double Blind, Placebo Controlled Studies of Ziprasidone in Outpatients with Bipolar IDepression (P.T.A.B. Mar. 11, 2...
|
|
Cite Document
2057 Exhibit: Fala, Latuda Lurasidone HCL Receives 2 New Indications for Usein B...
Document
IPR2020-01053, No. 2057 Exhibit - Fala, Latuda Lurasidone HCL Receives 2 New Indications for Usein Bipolar Depression as Monotherapy and as Adjunctive Therapy withLithium or Valproate (P...
|
|
Cite Document
2043 Exhibit: FDA Atypical Antipsychotic Drugs Information
Document
IPR2020-01053, No. 2043 Exhibit - FDA Atypical Antipsychotic Drugs Information (P.T.A.B. Mar. 11, 2021)
|
|
Cite Document
2079 Exhibit: Pareek, Factors Affecting Non Compliance to Psychotropic Drugs ofP...
Document
IPR2020-01053, No. 2079 Exhibit - Pareek, Factors Affecting Non Compliance to Psychotropic Drugs ofPatients with Psychosis as Perceived by their Family MembersAttending the Psychiatric O...
|
|
Cite Document
2088 Exhibit: Mak et al, Cost Savings Associated with Improved Adherence Among...
Document
IPR2020-01053, No. 2088 Exhibit - Mak et al, Cost Savings Associated with Improved Adherence AmongPatients with Schizophrenia Using Lurasidone (P.T.A.B. Mar. 11, 2021)
|
|
Cite Document
2086 Exhibit: Rajagopalan et al, Cost Utility Analysis of Lurasidone VersusAripipraz...
Document
IPR2020-01053, No. 2086 Exhibit - Rajagopalan et al, Cost Utility Analysis of Lurasidone VersusAripiprazole in Adults with Schizophrenia (P.T.A.B. Mar. 11, 2021)
|
|
Cite Document
